

RESEARCH

Open Access



Is the cholesterol-perfluoroalkyl substance association confounded by dietary fiber intake?: a Bayesian analysis of NHANES data with adjustment for measurement error in fiber intake

Matthew W Linakis¹, Paul Gustafson², Bruce C Allen³, Annette M Bachand⁴, Cynthia Van Landingham⁵, Debra R Keast⁶ and Matthew P Longnecker^{1*}

Abstract

Background: Serum concentrations of total cholesterol and related lipid measures have been associated with serum concentrations of per- and polyfluoroalkyl substances (PFAS) in humans, even among those with only background-level exposure to PFAS. Fiber is known to decrease serum cholesterol and a recent report based on National Health and Nutrition Examination Survey (NHANES) showed that PFAS and fiber are inversely associated. We hypothesized that confounding by dietary fiber may account for some of the association between cholesterol and PFAS.

Methods: We implemented a Bayesian correction for measurement error in estimated intake of dietary fiber to evaluate whether fiber confounds the cholesterol-PFAS association. The NHANES measure of diet, two 24-h recalls, allowed calculation of an estimate of the “true” long-term fiber intake for each subject. We fit models to the NHANES data on serum cholesterol and serum concentration of perfluorooctanoic acid (PFOA) and two other PFAS for 7,242 participants in NHANES.

Results: The Bayesian model, after adjustment for soluble fiber intake, suggested a decrease in the size of the coefficient for PFOA by 6.4% compared with the fiber-unadjusted model.

Conclusions: The results indicated that the association of serum cholesterol with PFAS was not substantially confounded by fiber intake.

Keywords: Serum cholesterol, PFAS, Confounding, Dietary fiber, Bayesian models, Measurement error correction

Background

Per- and polyfluoroalkyl substances (PFAS) have been used in manufacturing of a variety of products, including consumer-use products such as textiles that are stain

or fire resistant [1, 2]. In the general population exposure occurs mainly via contaminated food; other sources such as contaminated water are important in selected settings [3]. Most people in developed countries have detectable amounts of PFAS in their serum [3]. Epidemiological studies have suggested associations between serum concentrations of PFAS and serum concentrations of total cholesterol and related lipid measures in humans, even among those with only background-level exposures

*Correspondence: mlongnecker@ramboll.com

¹ Ramboll US Consulting, Inc., 3214 Charles B Root Wynd #130, Raleigh NC 27612, USA

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

[4, 5]. Although a few animal studies have suggested an increase in serum cholesterol with increasing PFAS dose [6, 7], most show a decrease in cholesterol [5]. Nonetheless, the PFAS – cholesterol association was proposed as the point of departure in risk assessments by the European Food Safety Authority (EFSA) [8] and the California Environmental Protection Agency [9]. A recent critique of the EFSA risk assessment questioned the causality of the PFAS – cholesterol association due to uncertainties about the biologic mechanism [10]. In addition, occupational studies among workers whose PFAS levels were above background have not consistently found evidence of associations between PFAS and cholesterol [11, 12]. In an epidemiologic study by Fitz-Simon et al., marked lowering of PFAS exposure results in no change in serum cholesterol [13]. Furthermore, a large epidemiological study with an unusually high exposure to perfluorooctanoic acid (PFOA) did not find evidence of an association between PFOA and cardiovascular disease [14]. Large doses of PFOA had no effect on serum cholesterol in a clinical trial [15]. Many potential biologic mechanisms that might account for the cholesterol-PFAS association in humans have been studied in experiments [5, 16]. For example, PFAS may alter cholesterol production by hepatocytes, alter the circulation of cholesterol in plasma, or interfere with bile acid metabolism or reabsorption from the intestine and thereby affect hepatic cholesterol production. However, many challenges have arisen in the interpretation of these data because of interspecies differences in cholesterol metabolism and diet (esp. fat content), uncertainties about the relevant doses in experimental models, and inconsistent results. More data from humanized mice may help resolve the issue, though other approaches may also be useful.

A possible explanation for the contradictory epidemiologic results is confounding by dietary fiber intake [5, 16]. This explanation is plausible because an inverse relationship between dietary fiber and serum cholesterol has been suggested for many years [17], and a recent report based on National Health and Nutrition Examination Survey (NHANES) provided evidence of an inverse association between serum PFAS and fiber intake among adults aged 20 years and older [18]. A simplified directed acyclic graph depicting the potential confounding is shown in Fig. 1. Because fiber decreases both serum cholesterol and serum PFAS, not adjusting for it in epidemiologic analyses could produce the appearance of a positive relation, even if none exists.

The biologic mechanisms underlying the relationships of fiber with serum PFAS and serum cholesterol are as follows. Soluble fiber is a bile acid sequestrant [19]. Bile acid sequestrants in the intestine have two key effects. First, they cause an upregulation of bile acid synthesis




Fig. 1 Directed acyclic graph showing relationships between fiber, PFAS, and cholesterol. Grey arrows indicate the direction of the association, specifically, fiber has an inverse relationship with PFAS concentration and cholesterol levels, while PFAS concentration has a positive correlation with cholesterol levels

in the liver, which lowers serum cholesterol [19]. Second, bile acid sequestrants have been shown to decrease serum PFAS by increasing fecal excretion, which is probably due to binding of PFAS by fiber [5, 20, 21].

We investigated the effect of confounding by fiber intake on the PFAS – cholesterol association using NHANES data. We focused on PFOA, perfluorooctane sulfonic acid (PFOS), and perfluorononanoic acid (PFNA) because these PFAS have been most consistently related to serum cholesterol in epidemiologic studies [4, 5]. Because of evidence suggesting a stronger inverse relationship between serum cholesterol and soluble dietary fiber than total dietary fiber [17], we conducted separate analyses for the two fiber variables. We recognized that due to day-to-day variation in fiber intake, error in measurement of fiber intake might result in an underestimate of the confounding it caused. To minimize such residual confounding, we implemented a Bayesian correction for measurement error [18, 22, 23]. Bayesian correction for measurement error has previously been described for an exposure of interest (e.g., [24]); in our context, however, the correction was for a confounding factor, meaning a related but slightly different approach was required, as described below.

Methods

Data and data manipulations

NHANES is an ongoing survey of civilian non-institutionalized people residing in the U.S., and it is conducted using a complex sampling design that oversamples selected minorities, income groups, and ages [25]. Data from NHANES are publicly available from (<https://www.cdc.gov/nchs/nhanes/Default.aspx>). From 2003–2016,

cholesterol levels were measured among NHANES participants aged 12 years and older who provided a blood sample. PFAS levels, specifically PFOA, PFOS, and PFNA, were measured in a random sample of one-third of these study subjects. All NHANES participants were asked to complete a 24-h dietary recall on two occasions 3–10 days apart [26]. The first interview took place in person and the second interview was conducted over the phone. NHANES data includes daily energy (kcal) and daily total dietary fiber (g) intake as determined by USDA using their food composition data, i.e., the U.S. Department of Agriculture (USDA) Food and Nutrient Database for Dietary Studies (FNDDS), to calculate energy (kcal) and total dietary fiber (g) intake from foods reported in NHANES dietary interviews. A food composition database developed by the Nutrition Coordinating Center (NCC), University of Minnesota, Minneapolis, MN, i.e., the NCC Food and Nutrient Database, was used to add soluble fiber data to the FNDDS, which allowed for the calculation of soluble fiber intake by NHANES respondents (Supplemental materials, S1). The fiber intake data reflect both the amount and fiber composition of foods consumed. To focus our analyses on diet composition, we estimated daily fiber intake relative to the daily caloric intake. We calculated the energy intake-adjusted fiber variables as the residuals of linear regression models of dietary fiber (g/d) on energy (kcal/d) intake [27].

We limited our study population to NHANES participants aged 20 years or older with complete serum PFAS and serum cholesterol data, and 2 days of complete dietary intake data. More than 99% of our study population had detectable concentrations of PFOA, PFOS, and PFNA in serum. For years 2013–2014 and 2015–2016, in which the linear and branched isomers of PFOA and PFOS were measured separately, we calculated the sum of these isomers. PFAS values below the limit of detection (LOD) were imputed by the CDC as $\text{LOD}/\sqrt{2}$.

To ensure that fiber intake did not act as a surrogate for other confounding variables, we extracted data for additional variables from the NHANES data set. We considered age, sex, race/ethnicity, body mass index, income to poverty ratio, smoking, dietary saturated fat, dietary cholesterol, and NHANES wave as “secondary” confounders. Additional details are provided in the Supplementary Materials, Section S2 and Figure S1.

To reduce the influence of outliers on the study results, we excluded subjects whose ln-transformed energy intake-adjusted fiber values (shifted by 40 g/d to avoid taking the log of a number ≤ 0) or ln-transformed cholesterol value fell outside the 99th percentile of the normal distribution, i.e., >2.57 standard deviations from the mean. Ln transformations were required to normalize the data. We also excluded subjects who reported using cholesterol-lowering

medications (cholestyramine, colesvelam, colestipol, ezetimibe, orlistat, any statin, or Vytarin). Our analyses were based on 7,242 subjects with complete data.

Ordinary least squares regression

As a reference point, we conducted ordinary least squares (OLS) regression with ln-transformed cholesterol as the outcome variable and ln-transformed energy intake-adjusted fiber (shifted by 40 g/d) as the confounding variable of interest, with fiber intake defined as the average over the two days. We created separate models for the three PFAS compounds and we considered a change of $\geq 10\%$ in the coefficient for the PFAS compound after adjusting for fiber as evidence of confounding [28]. The secondary confounders were included in all models and all non-categorical confounders were centered. In sensitivity analyses, we evaluated the addition of a quadratic PFAS term with Akaike Information Criterion. Note that in OLS regression, the success of adjustment for confounding is based on the assumption that the confounder can be observed without measurement error.

Bayesian adjustment for measurement error

Several frequentist and Bayesian methods have been suggested to correct for measurement error in model covariates [22–24, 29–31]. Bayesian analyses estimate the posterior distribution of unknown parameters based on prior information combined with information gained from available data, and they generally allow for the greatest flexibility with few assumptions.

Following an approach outlined by Bartlett and Keogh [24], we assumed that Y is the response variable (cholesterol), X is the exposure variable (PFOA, PFOS, or PFNA), F is the confounding variable of interest (fiber intake), and C represents the secondary confounding variables. If F could be observed, then a regression model such as

$$(Y|X, F, C) \sim N\left(\beta_0 + \beta_X X + \beta_F F + \beta_c^T C, \sigma^2\right) \quad (1)$$

could be fit directly, and this model contains the parameters of interest. Note that with (1) being the relationship of interest, we would include components in C that we suspect also confound the exposure-disease relationship (as we suspect of F).

With F being latent however, we can't fit (1) alone to data. We must augment with two further models. The first of these models is $(F|X, C)$, with a natural form being

$$(F|X, C) \sim N\left(\gamma_0 + \gamma_X X + \gamma_c^T C, \omega^2\right) \quad (2)$$

An additional component is needed to link the latent and measured values of dietary fiber. Presume that subjects have two noisy measurements, F_1^* and F_2^* . In full

generality, it is necessary to complement Eqs. (1) and (2) with a model for $(F_1^*, F_2^* | EY, X, C)$. However, several simplifications can be made. First, a supposition that the two measurements are “pure” replicates in the sense of being conditionally independent of one another given (EY, X, C) , may be justifiable. This reduces a model for the bivariate pair of measurements into two models for the univariate measurements, i.e., for $(F_j^* | EY, X, C)$, for $j=1,2$. Second, a “nondifferential” measurement error assumption may be justifiable, whereby the measurement error is not affected by (Y, X, C) . This then reduces the model specification task to models for $(F_j^* | F)$, for $j=1,2$. Then finally it might be justifiable to posit no systematic bias in the measurement. In such a case, a specification as simple as

$$(F_j^* | F) \sim N(F, \tau^2) \tag{3}$$

for $j=1,2$, would suffice. Although subtleties of the present problem may call for a richer model, an initial evaluation as described is an important first step.

Conceptually, it is important to note that together (1), (2), and (3) prescribe a joint distribution for $(F_1^*, F_2^*, EY | X, C)$, and therefore a joint distribution for $(F_1^*, F_2^*, Y | X, C)$. Since the latter involves only observables, it provides a foundation for likelihood or Bayesian inference concerning all the unknown regression coefficients (β and γ) and variance parameters ($\sigma^2, \omega^2, \tau^2$).

Operationally, Markov chain Monte Carlo software operates by sampling from the joint posterior distribution of latent variables and parameters given observed variables. Thus, the software output is simulated samples of $(F_{1:n}, \beta, \gamma, \sigma^2, \omega^2, \tau^2)$, where n is the number of subjects.

Bayesian analyses

We used Stan statistical software (v 2.27) interfaced with R software (v 4.1.0) using the “RStan” package (v 2.21.2) [32]. We used a virtual machine with 4 virtual CPUs (Microsoft Azure Standard D4 v4) and 16 GiB of RAM. We used 4 chains with a burn-in proportion of 0.5, a maximum tree depth of 15, 2,500 iterations, and set the target average acceptance probability to 0.8. For all analyses, we used mixing and convergence diagnostics recommended by Gelman et al. [33]. We compared the parameter estimates for each PFAS between the three models, one unadjusted and two adjusted for fiber (total and soluble). We also examined the influence of using informative priors for regression coefficients in the Bayesian models (1)-(3) (not shown). The informative priors were normally distributed with parameters based on published data (Supplementary Material Sect. 3, Tables 1 and 2). We present results based on the models with informative priors because they converged more quickly than models with uninformative priors and there

were no substantial differences in the results (not shown). The Stan model, R code, and data required to replicate both the OLS and Bayesian analyses have been provided in a supplemental file (Supplemental_Code.zip).

Results

The descriptive statistics for the study variables are presented in Supplementary Material Table S1. As expected, based on the NHANES sampling design, selected minority racial and ethnic groups were overrepresented. There were more women than men because statin users (primarily males) were excluded. Other than minor differences due to the sampling design, the study population and the U.S. population were similar [18].

OLS regression results did not meaningfully depend on the NHANES sampling design and, to simplify the Bayesian analyses, we conducted unweighted analyses. Table 1 shows the estimated adjusted coefficients and their error estimates for fiber and PFOA from OLS and Bayesian models of ln-transformed cholesterol. OLS regression suggested a more pronounced association between fiber and cholesterol for soluble than for total fiber. After adjusting for measurement error in the Bayesian analyses, the coefficients for the fiber variables were more inverse (larger negative coefficient). The coefficients for PFOA were similar in the fiber-unadjusted OLS and Bayesian analyses and adjusting for fiber had a nominal effect (e.g., coefficients were 5.4% [OLS] and 6.4% [Bayesian] smaller after adjustment for soluble fiber). Error estimates for the PFOA coefficients were similar for the OLS-based and the Bayesian-based coefficients. Results for PFOS and PFNA were similar to those shown here although

Table 1 Coefficients^a (error estimates^b) for fiber(ln[g/d])^c and PFOA (ng/ml) in multivariable models^d of ln(serum cholesterol), according to fiber variable included in model and type of model; $n = 7,242$

Fiber variable ^c included in model	ln-transformed energy intake-adjusted fiber (ln[g/d])		PFOA (ng/ml)	
	OLS	Bayesian	OLS	Bayesian
None	N/A	N/A	2.59 (0.75)	2.66 (0.71)
Total fiber	-1.92 (1.58)	-2.35 (1.58)	2.53 (0.75)	2.59 (0.72)
Soluble fiber	-2.90 (1.06)	-3.53 (1.49)	2.45 (0.75)	2.49 (0.72)

^a To simplify the presentation coefficients and error estimates were multiplied by 10^{-3} for PFOA and 10^{-2} for fiber

^b Ordinary least squares (OLS) error estimates are standard errors and Bayesian error estimates are standard deviations

^c Modeled as ln-transformed energy intake-adjusted fiber

^d All models were adjusted for the secondary covariates energy intake, saturated fat intake, dietary cholesterol intake, age, sex, race/ethnicity (5 categories), income to poverty ratio, smoking (4 categories, treated as an ordinal variable), and a linear and a quadratic wave variable

adjustment for fiber led to less attenuation of the coefficients (Supplemental Table S2). Results for Eq. (1) for all full models are shown in the Supplemental Materials (Tables S3–S5).

Discussion

We investigated the effect of confounding by fiber intake on the association between PFAS compounds and serum cholesterol using OLS regression. Based on NHANES data, we considered total and soluble fiber and focused our analyses on diet composition. To determine if measurement error in the fiber variables affected our ability to adjust for confounding, we used Bayesian methods to correct for measurement error. We focused on the PFAS compounds PFOA, PFOS, and PFNA because previous studies have suggested that these compounds are positively associated with serum cholesterol levels [4, 34–36] and inversely associated with dietary fiber [18]. More than 99% of our study subjects had detectable concentrations of the three compounds. Although the NHANES data are based on a complex sampling design, adjusting for the variables that determined the sampling fractions (age, race/ethnicity, income) allowed us to conduct unweighted analyses [37], which simplified the Bayesian approach.

While mechanisms involving hepatic, lipoprotein, and bile acid metabolism have been proposed as explanations for observed association between PFAS and serum cholesterol in humans, a clear mechanism has not been elucidated [5, 16]. Both Andersen et al. and Fragki et al. suggested that the PFAS – cholesterol association may be explained by uncontrolled confounding by fiber intake. In our analyses of the association based on data from NHANES 2003–2016 ($n=7,242$), adjusting for fiber had a nominal effect in both OLS regression analyses and Bayesian analyses that adjusted for measurement error.

Our study had several limitations. First, use of NHANES data meant our analyses were cross-sectional. However, the cholesterol-fiber interrelations may have been near a steady state. The three PFAS studied have half-lives on the order of years [12, 38–40] and serum cholesterol measures vary only a small amount from day-to-day [41, 42]. Another limitation was that the Bayesian analyses were based on multiple assumptions which may have been violated in our study. This included the unlikely assumption that, except for fiber, all model covariates were measured without error. We further assumed that measurement error affecting the fiber variable was unbiased despite suggestions that relying on recall can lead to biased estimates of dietary intake [43]. The Bayesian analyses on the full data set ($n=7,242$) were computationally intensive and took an extraordinarily long time to run. They were only practical after reducing the number

of iterations to 2,500 per chain and decreasing the target average acceptance probability to 0.8. Each analysis still took approximately 10 days to complete but chain convergence was acceptable. Implementing alternative approaches such as approximate Bayesian inference (e.g., the R-INLA package (r.inla.org)) could be considered in the future. Strengths of our study included our focus on diet composition by estimating fiber intake relative to total caloric intake, and the comparison of results for total and soluble fiber.

Conclusions

Our findings suggest that adjusting the association for fiber had a nominal effect on the results and that adjusting for measurement error did not meaningfully change the results. The associations between PFAS compounds and cholesterol in serum seem unlikely to be explained by confounding by dietary fiber intake. Elucidation of the biologic mechanism accounting for the association will require laboratory experiments, possibly in humanized mice.

Abbreviations

PFAS: Per- and polyfluoroalkyl substances; NHANES: National Health and Nutrition Examination Survey; PFOA: Perfluorooctanoic acid; EFSA: European Food Safety Authority; PFOS: Perfluorooctane sulfonic acid; PFNA: Perfluorononanoic acid; USDA: U.S. Department of Agriculture; FNDDS: Food and Nutrient Database for Dietary Studies; NCC: Nutrition Coordinating Center; LOD: Limit of Detection; OLS: Ordinary Least Squares.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12940-022-00923-2>.

Additional file 1.

Additional file 2.

Additional file 3.

Additional file 4.

Acknowledgements

Dr. Michael W. Dzierlenga provided critical comments on an early draft of the manuscript.

Authors' contributions

MWL: Revised the Bayesian code so that it would run on the full dataset, conducted all Bayesian analyses, reviewed manuscript drafts and provided critical comments. PG: Guided the Bayesian methodology, reviewed manuscript drafts and provided critical comments. BCA: Wrote the initial draft of the Bayesian code, reviewed manuscript drafts and provided critical comments. AMB: Contributed to the development of the study strategy, did extensive rewriting of an early manuscript draft, reviewed manuscript drafts and provided critical comments. CVL: Prepared the NHANES data for analysis, reviewed manuscript drafts and provided critical comments. DRK: Calculated soluble fiber intake for subjects in the analysis, reviewed manuscript drafts and provided critical comments. MPL: Conceived of the study, designed it, obtained funding for it, wrote the initial draft of the manuscript, and incorporated coauthor's comments into the final version. The author(s) read and approved the final manuscript.

Funding

This project was funded through a contract between 3 M and Ramboll. Ramboll is an international science and engineering company that provided salary compensation to the authors. None of the authors are currently engaged to testify as experts on behalf of the sponsors in litigation related to the compound discussed in this manuscript.

Availability of data and materials

The NHANES and FNDDS databases are freely available and can be found at the following locations:

NHANES: <https://www.cdc.gov/nchs/nhanes/Default.aspx>

FNDDS: <https://www.ars.usda.gov/northeast-area/beltsville-md-bhnrc/beltsville-human-nutrition-research-center/food-surveys-research-group/docs/fndds-download-databases/>

Additionally, the NCC Food and Nutrient database can be licensed from the following location: <http://www.ncc.umn.edu/food-and-nutrient-database/>. Because the last database is not freely available, we have also provided our database (data.csv) and our database with data dictionary (data_w_dictionary.xlsx) in the Supplemental Materials.

Declarations

Ethics approval and consent to participate

NHANES obtained written informed consent from all participants, and all data are available on the NHANES website in a de-identified form. Data were collected by the National Center for Health Statistics (NCHS) and approved by their ethical review board under Protocol #2021–05.

Consent for publication

Not applicable.

Competing interests

3 M, the company that funded this research, previously used PFOA and precursors to PFOS in manufacturing. 3 M was not involved in the preparation of the manuscript. The authors retained sole control of the manuscript content and the findings, and statements in this paper are those of the authors and not those of the author's employer or the sponsors. No authors were directly compensated by 3 M.

Author details

¹Ramboll US Consulting, Inc., 3214 Charles B Root Wynd #130, Raleigh NC 27612, USA. ²Department of Statistics, University of British Columbia, Vancouver, Canada. ³Independent consultant, Chapel Hill, North Carolina, USA. ⁴Ramboll US Consulting, Inc, Amherst, Massachusetts, USA. ⁵Ramboll US Consulting, Inc, Monroe, Louisiana, USA. ⁶Food & Nutrition Database Research, Inc, Bangor, PA, USA.

Received: 1 September 2022 Accepted: 24 October 2022

Published online: 22 November 2022

References

- Buck RC, Franklin J, Berger U, Conder JM, Cousins IT, de Voogt P, et al. Perfluoroalkyl and Polyfluoroalkyl Substances in the Environment: Terminology, Classification, and Origins. *Integr Environ Assess Manag*. 2011;7:513–41.
- Peaslee GF, Wilkinson JT, McGuinness SR, Tighe M, Caterisano N, Lee S, et al. Another Pathway for Firefighter Exposure to Per- and Polyfluoroalkyl Substances: Firefighter Textiles. *Environ Sci Technol Lett American Chemical Society*. 2020;7:594–9.
- Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. *J Expo Sci Environ Epidemiol*. 2019;29:131–47.
- Dong Z, Wang H, Yu YY, Li YB, Naidu R, Liu Y. Using 2003–2014 U.S. NHANES data to determine the associations between per- and polyfluoroalkyl substances and cholesterol: Trend and implications. *Ecotoxicol Environ Saf*. 2019;173:461–8.
- Andersen ME, Hagenbuch B, Apte U, Corton JC, Fletcher T, Lau C, et al. Why is elevation of serum cholesterol associated with exposure to perfluoroalkyl substances (PFAS) in humans? A workshop report on potential mechanisms. *Toxicology*. 2021;459:152845.
- Butenhoff J, Costa G, Elcombe C, Farrar D, Hansen K, Iwai H, et al. Toxicity of ammonium perfluorooctanoate in male cynomolgus monkeys after oral dosing for 6 months. *Toxicol Sci*. 2002;69:244–57.
- Chang S, Allen BC, Andres KL, Ehresman DJ, Falvo R, Provencher A, et al. Evaluation of Serum Lipid, Thyroid, and Hepatic Clinical Chemistries in Association With Serum Perfluorooctanesulfonate (PFOS) in Cynomolgus Monkeys After Oral Dosing With Potassium PFOS. *Toxicol Sci*. 2017;156:387–401.
- EFSA Panel on Contaminants in the Food Chain (CONTAM), Knutsen HK, Alexander J, Barregård L, Bignami M, Brüschweiler B, et al. Risk to human health related to the presence of perfluorooctane sulfonic acid and perfluorooctanoic acid in food. *EFSA J*. 2018;16:e05194.
- Pesticide and Environmental Toxicology Branch, Office of Environmental Health Hazard Assessment, California Environmental Protection Agency. FIRST PUBLIC REVIEW DRAFT: Perfluorooctanoic Acid and Perfluorooctane Sulfonic Acid in Drinking Water [Internet]. 2021 Jul. Available from: <https://oehha.ca.gov/media/downloads/cnr/pfoapfosphgdraft061021.pdf>
- EFSA Panel on Contaminants in the Food Chain (CONTAM). Minutes of the expert meeting on perfluorooctane sulfonic acid and perfluorooctanoic acid in food assessment [Internet]. 2018 p. 25. Report No.: EFSA/CONTAM/3503. Available from: <https://www.efsa.europa.eu/sites/default/files/news/efsa-contam-3503.pdf>
- Olsen GW, Burris JM, Burlew MM, Mandel JH. Plasma cholecystokinin and hepatic enzymes, cholesterol and lipoproteins in ammonium perfluorooctanoate production workers. *Drug Chem Toxicol*. 2000;23:603–20.
- Olsen GW, Burris JM, Ehresman DJ, Froehlich JW, Seacat AM, Butenhoff JL, et al. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorocarbon production workers. *Environ Health Perspect*. 2007;115:1298–305.
- Fitz-Simon N, Fletcher T, Luster MI, Steenland K, Calafat AM, Kato K, et al. Reductions in serum lipids with a 4-year decline in serum perfluorooctanoic acid and perfluorooctanesulfonic acid. *Epidemiol*. 2013;24:569–76.
- Winqvist A, Steenland K. Modeled PFOA exposure and coronary artery disease, hypertension, and high cholesterol in community and worker cohorts. *Environ Health Perspect*. 2014;122:1299–305.
- Convertino M, Church TR, Olsen GW, Liu Y, Doyle E, Elcombe CR, et al. Stochastic Pharmacokinetic-Pharmacodynamic Modeling for Assessing the Systemic Health Risk of Perfluorooctanoate (PFOA). *Toxicol Sci*. 2018;163:293–306.
- Fragki S, Dirven H, Fletcher T, Gras-Kraupp B, Bjerve Gützkow K, Hoogenboom R, et al. Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not? *Crit Rev Toxicol*. 2021;51:141–64.
- Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr*. 1999;69:30–42.
- Dzierlenga MW, Keast DR, Longnecker MP. The concentration of several perfluoroalkyl acids in serum appears to be reduced by dietary fiber. *Environ Int*. 2021;146:106292.
- Sorrentino MJ. An update on statin alternatives and adjuncts. *Clin Lipidol*. 2012;7:721–30.
- Genuis SJ, Birkholz D, Ralitsch M, Thibault N. Human detoxification of perfluorinated compounds. *Public Health*. 2010;124:367–75.
- Johnson J. Cholestyramine-enhanced fecal elimination of carbon-14 in rats after administration of ammonium [14C]perfluorooctanoate or potassium [14C]perfluorooctanesulfonate. *Fundam Appl Toxicol*. 1984;4:972–6.
- Gustafson P. Measurement Error and Misclassification in Statistics and Epidemiology: Impacts and Bayesian Adjustments. New York: Chapman and Hall/CRC; 2003.
- Gustafson P. Bayesian Inference for Partially Identified Models: Exploring the Limits of Limited Data. New York: Chapman and Hall/CRC; 2015.
- Bartlett JW, Keogh RH. Bayesian correction for covariate measurement error: A frequentist evaluation and comparison with regression calibration. *Stat Methods Med Res*. 2018;27:1695–708.

25. Zipf G, Chiappa M, Porter KS, Ostchega Y, Lewis BG, Dostal J. National health and nutrition examination survey: plan and operations, 1999–2010. *Vital Health Stat.* 2013;1:1–37.
26. CDC. NHANES Questionnaires, Datasets, and Related Documentation [Internet]. 2004 [cited 2022 Apr 21]. Available from: <https://www.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2003>
27. Willett WC, Howe GR, Kushi LH. Adjustment for total energy intake in epidemiologic studies. *Am J Clin Nutr.* 1997;65:1220S–1228S discussion 1229S–1231S.
28. Rothman KJ, Lash TL, Greenland S. *Modern Epidemiology*. Third. Philadelphia: Lippincott Williams & Wilkins; 2008.
29. Keogh RH, Shaw PA, Gustafson P, Carroll RJ, Deffner V, Dodd KW, et al. STRATOS guidance document on measurement error and misclassification of variables in observational epidemiology: Part 1-Basic theory and simple methods of adjustment. *Stat Med.* 2020;39:2197–231.
30. Richardson S, Gilks WR. A Bayesian approach to measurement error problems in epidemiology using conditional independence models. *Am J Epidemiol.* 1993;138:430–42.
31. Shaw PA, Gustafson P, Carroll RJ, Deffner V, Dodd KW, Keogh RH, et al. STRATOS guidance document on measurement error and misclassification of variables in observational epidemiology: Part 2-More complex methods of adjustment and advanced topics. *Stat Med.* 2020;39:2232–63.
32. Stan Development Team. *Stan User's Guide* [Internet]. 2021 [cited 2021 Nov 29]. Available from: <https://mc-stan.org/users/citations/>.
33. Gelman A, Carlin JB, Stern HS, Dunson DB, Vehtari A, Rubin DB. *Bayesian data analysis*. 3rd ed. Boca Raton: CRC Press; 2014.
34. Geiger SD, Xiao J, Ducatman A, Frisbee S, Innes K, Shankar A. The association between PFOA, PFOS and serum lipid levels in adolescents. *Chemosphere Elsevier.* 2014;98:78–83.
35. Nelson JW, Hatch EE, Webster TF. Exposure to polyfluoroalkyl chemicals and cholesterol, body weight, and insulin resistance in the general US population. *Environmental health perspectives. National Inst Environ Health Sciences.* 2010;118:197–202.
36. Steenland K, Tinker S, Frisbee S, Ducatman A, Vaccarino V. Association of perfluorooctanoic acid and perfluorooctane sulfonate with serum lipids among adults living near a chemical plant. *Am J Epidemiol.* 2009;170:1268–78 Oxford University Press.
37. Korn EL, Graubard BI. Epidemiologic studies utilizing surveys: accounting for the sampling design. *Am J Public Health.* 1991;81:1166–73.
38. Li Y, Fletcher T, Mucs D, Scott K, Lindh CH, Tallving P, et al. Half-lives of PFOS, PFHxS and PFOA after end of exposure to contaminated drinking water. *Occup Environ Med.* 2018;75:46–51.
39. Xu Y, Fletcher T, Pineda D, Lindh CH, Nilsson C, Glynn A, et al. Serum Half-Lives for Short- and Long-Chain Perfluoroalkyl Acids after Ceasing Exposure from Drinking Water Contaminated by Firefighting Foam. *Environ Health Perspect.* 2020;128:77004.
40. Zhang Y, Beesoon S, Zhu L, Martin JW. Biomonitoring of perfluoroalkyl acids in human urine and estimates of biological half-life. *Environ Sci Technol.* 2013;47:10619–27.
41. Hegsted DM, Nicolosi RJ. Individual variation in serum cholesterol levels. *Proc Natl Acad Sci U S A.* 1987;84:6259–61.
42. Pereira MA, Weggemans RM, Jacobs DR, Hannan PJ, Zock PL, Ordovas JM, et al. Within-person variation in serum lipids: implications for clinical trials. *Int J Epidemiol.* 2004;33:534–41.
43. Karvetti RL, Knuts LR. Validity of the 24-hour dietary recall. *J Am Diet Assoc.* 1985;85:1437–42.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

